DAYVIGO

This brand name is authorized in Canada, Hong Kong, Israel, Japan, United States

Active ingredients

The drug DAYVIGO contains one active pharmaceutical ingredient (API):

1 Lemborexant UNII 0K5743G68X - LEMBOREXANT

Lemborexant is an orexin receptor antagonist. The orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
DAYVIGO Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N05CM	Other hypnotics and sedatives	N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives
Discover more medicines within N05CM

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02507366, 02507374
Country: HK	Department of Health Drug Office	Identifier(s): 67001, 67002
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9411, 9412
Country: JP	医薬品医療機器総合機構	Identifier(s): 1190027F1022, 1190027F2029, 1190027F3025
Country: US	FDA, National Drug Code	Identifier(s): 62856-405, 62856-410, 62856-455